We are looking for Canadian industry partners to fully exploit our R&D solutions. We transfer knowledge to our industry partners through patented technologies that have high potential commercial value — helping businesses develop cohesive, integrated and market-ready solutions that attract investment and drive revenue.
To provide easy access to some of Canada's leading technologies we make available cost-effective, non-exclusive, single-year, renewable research and development licenses according to a set of fixed terms and conditions.
Express licences (which are identified with the word Express in their titles below) are available at a rate of $1,000 Canadian per year, per listed technology for a specific business entity, or $750 Canadian per year, per listed technology for two or more technologies.
Select your industry category below to learn which NRC licensing opportunities can benefit your organization.
- 33 results found
Infections caused by Moraxella catarrhalis are often resistant to antibiotics such as penicillin, ampicillin, and amoxicillin. To prevent the painful infections that M. catarrhalis can cause and to address issues surrounding antimicrobial resistance, the NRC has engineered a vaccine candidate that can be licensed for further development, or advanced toward clinical trials in collaboration with our vaccine experts.